Lupin gets market approval of Atovaquone oral suspension By USFDA
Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
New Delhi: Drug firm Lupin said it has received a approval from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia. The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
The product is a generic version of GlaxoSmithKline LLC's Mepron oral suspension in the same strength, it added.
As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around USD 117.4 million in the US, Lupin said.
The product is "indicated for the prevention and acute oral treatment of mild-to-moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole," it added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd